

1 **Chemical/technical risk analysis of a new multidirectional nebulizer (MDN)**
2 **and its clinical implementation for the safe administration of**
3 **Pressurized Intraperitoneal Aerosol Chemotherapy (MDN-PIPAC)**

4

5

Short title:

6

MDN-PIPAC is feasible and safe

7

8

Fabian Kockelmann, MD¹, Daniel Göhler, Dipl.-Ing.^{2,3}, Sarah Barbey⁴, Mehdi Ouaiissi, Prof.

9

MD, PhD^{5,6}, Jürgen Zieren, Prof, MD¹, Urs Giger-Pabst, Prof, MD^{5,7}

10

11 ¹ Department of Surgery, Klinikum Dortmund, Hospital of the Witten/Herdecke University,
12 Germany

13 ² Topas GmbH, Dresden, Germany

14 ³ Research Group Mechanical Process Engineering, Institute of Process Engineering and
15 Environmental Technology, Technische Universität Dresden, Dresden, Germany

16 ⁴ Plateforme Pixanim, INRAE PRC, 37380, Nouzilly, France

17 ⁵ EA4245 Transplantation, Immunologie, Inflammation, Université de Tours, France

18 ⁶ Department of Digestive, Oncological, Endocrine, Hepato-Biliary, Pancreatic and Liver
19 Transplant Surgery, University Hospital of Tours, France

20 ⁷ Fliedner Fachhochschule, University of Applied Sciences, Düsseldorf, Germany

21

22

23

24 Correspondence:

25 Professor Urs Giger-Pabst, MD

26 Fliedner Fachhochschule

27 University of Applied Sciences Düsseldorf, Germany

28 Phone: +49 (0) 163 729 44 07

29 Email: ursgiger@gmx.net

30 **KEY WORDS**

31 PIPAC, Multi-directional nebulizer (MDN), chemical compatibility, chemical risk analysis,
32 CT-peritoneography, clinical safety, feasibility

33

34 **ABBREVIATIONS**

35 AET Analytical Evaluation Threshold (ISO 10993-18 (2020))
36 BSA Body Surface Area calculated according to DuBois
37 CE Conformité Européenne
38 DGAV Deutsche Gesellschaft für Allgemein- und Viszeralchirurgie
39 ECOG Eastern Cooperative Oncology Group
40 FDA U.S. Food and Drug Administration
41 GC-MS Gas Chromatography coupled with Mass Spectrometry
42 HSGC-MS Head-space Gas Chromatography coupled with Mass Spectrometry
43 IC Ion Chromatography
44 ICP-OES Inductively Coupled Plasma Atomic Emission Spectrometry
45 LC-MS Liquid phase chromatography □ coupled to a Mass Spectrometer
46 MDN Multi-Directional Nebulizer (Quattro JetTM, REGER, Medizintechnik
47 GmbH, Villigendorf, Germany)
48 PCI Peritoneal Carcinomatosis Index according to Sugarbaker
49 PIPAC Pressurized IntraPeritoneal Aerosol Chemotherapy
50 PSM Peritoneal Surface Malignancies
51 RIPAC Rotational intraperitoneal aerosol chemotherapy

52 SDN Single direction nebulizer

53 HD/HP PIPAC High dosage/high pressure pressurized intraperitoneal chemotherapy

54

55 **AUTHOR CONTRIBUTIONS**

56 Fabian Kockelmann, Urs Giger-Pabst: study design, coordination of study, data acquisition,
57 data interpretation, logistics, drafting of manuscript and critical revision for important content
58 of the manuscript

59 Daniel Göhler and Mehdi Ouaiissi: drafting of the manuscript and intellectual and scientific
60 contributions depending on their field of expertise

61 Sarah Barbey: study protocol, coordination of animal experiments and perioperative
62 management of animals

63 Jürgen Zieren: study design, PIPAC procedures, data acquisition, data interpretation, logistics,
64 drafting of manuscript and critical revision for important content of the manuscript

65

66 **DISCLOSURE**

67 All authors have no conflicts of interest or financial ties to disclose. The animal experiments,
68 were funded by the Association Tourangelle de recherche en oncologie du val de Loire (AT-
69 ROVL). All data produced in the present study are available upon reasonable request to the
70 authors All data produced in the present study are available upon reasonable request to the
71 authors.

72

73

74 **MINI ABSTRACT**

75 Toxicological analyses confirm that doxorubicin, cisplatin and oxaliplatin nebulized with the
76 MDN do not release leachables that pose a toxicological risk to patients. Through technical
77 risk analysis and PIPAC simulations, a safety concept for the administration of MDN-PIPAC
78 was established. No technical/medical intraoperative adverse events were observed. The
79 perioperative course was comparable to that of the conventional axial single-direction
80 nebulizer (SDN) PIPAC.

81

82 **ABSTRACT**

83 **Background/Aim:** To test the chemoresistance of a multi-directional nebulizer (MDN) and to
84 establish and implement a perioperative clinical safety concept for its clinical use to deliver
85 pressurised intraperitoneal aerosol chemotherapy (MDN-PIPAC).

86 *Study design:* Ex-vivo nebulization of cytostatic drugs with the MDN device to assess
87 chemoresistance/toxicological risks. Establishment of a perioperative safety concept for the
88 clinical administration of MDN-PIPAC by ex- and in-vivo porcine simulation studies.
89 Unicentric case series of 30 MDN-PIPACs in patients with peritoneal surface malignancies
90 (PSM). Endpoints were intraoperative adverse events and perioperative complications
91 (Clavien-Dindo).

92 *Results:* Toxicological studies/risk assessment confirm the safety of administering PIPAC
93 with the MDN. The horizontal nozzles must protrude at least 7 mm beyond the most distal
94 end of the trocar tip and lateral tilting should be prevented by fixation of the device in a
95 single-arm holder. A total of 21 patients (male/female ratio: 2:1) with a mean age of 62
96 (range: 38-86) years underwent 30 consecutive MDN-PIPACs for peritoneal surface
97 malignancies of different origin. ECOG 0 and 1 were seen in five and 16 patients,

98 respectively. Thirteen, seven and one patient underwent one, two and three MDN-PIPACs,
99 respectively. Two patients received only one cycle of MDN-PIPAC because they were
100 considered candidates for cytoreductive surgery and heated intraperitoneal chemotherapy.
101 There were no intraoperative technical/medical problems observed. Four patients suffered
102 from postoperative grade I complications.

103 *Conclusions:* Compounds leached during chemotherapy nebulization with the MDN are
104 toxicologically safe. MDN-PIPAC administration is safe and the postoperative course
105 comparable to that of the conventional PIPAC nebulizer.

106

107 **1.0 INTRODUCTION**

108 For more than a decade, pressurised intraperitoneal aerosol chemotherapy (PIPAC) has been
109 used worldwide for the treatment of peritoneal surface malignancies (PSM). Clinical results
110 have been encouraging, but data from prospective randomised trials clearly demonstrating the
111 efficacy of this treatment are still lacking [1 - 3]. A common feature of all currently available
112 nebulizers for PIPAC is that all nebulizers have only one atomizing unit (axial single-
113 direction nebulizer (SDN)), which ejects the chemotherapy droplets in an axial direction. The
114 majority (97.5% by volume) of the nebulized chemotherapy directly impacts with the
115 peritoneum located below the atomizer orifice [4]. It has also been suggested that the locally
116 high drug deposition that occurs with the use of conventional PIPAC nebulizers leads to
117 potential local toxicity that could result in an increase in perioperative complications,
118 especially when additional surgical procedures such as complex adhesiolysis or bowel
119 resection are performed concurrently with PIPAC [5 - 7]. However, recent clinical data seem
120 to relativise an increased complication rate with PIPAC and concomitant extended surgery
121 [8]. However, for such reasons, PIPAC nebulizer technology has been extended by integrating
122 three additional atomizer units into the nebulizer head in the horizontal plane at a distance of

123 120 degrees. Initial ex-vivo data from such multi-directional nebulizer (MDN) report an
124 improved spatial drug distribution [2, 9].

125 For some time now, a CE approved MDN has been available for clinical off-label PIPAC use
126 (MDN-PIPAC). However, since there are still no documented in-vivo applications worldwide,
127 we have decided to conduct additional extensive preclinical testing before the first clinical
128 application. The aim of this study was to i) investigate any toxicological risk posed by
129 leachables from the device when used in conjunction with cytotoxic drugs, ii) develop an
130 intraoperative safety concept for the administration of MDN-PIPAC using an ex-vivo PIPAC
131 model, in-vivo animal CT-peritoneography and iii) retrospective analysis of a consecutive
132 case series of 30 patients to evaluate the perioperative safety of MDN-PIPAC in patients with
133 peritoneal surface malignancies (PSM).

134

135 **2.0 MATERIAL & METHODS**

136 *2.1 Research sites and institutes:* Nebulization for cytostatic drug compatibility/toxicology
137 studies of the MDN and the in-vivo animal experiments were carried out at the French
138 National Research Institute for Agriculture, Food and Environment (INRAE), Centre Val de
139 Loire Nouzilly, France. Chemical characterisation and toxicological evaluation by
140 RESCOLL, Pessac, France and TentaConsult Pharma & Med GmbH, Münster, Germany,
141 respectively. The ex-vivo MDN-PIPAC simulation studies and the Schlieren investigations
142 were carried out at the Bauhaus University Weimar, Germany.

143 *2.2 MDN chemotherapy compatibility study:* Doxorubicin, cisplatin and oxaliplatin were
144 purchased from Hexal AG, Holzkirchen, Germany, Accord Healthcare B.V. Utrecht, The
145 Netherlands and Medac GmbH, Wedel, Germany. Drug doses (doxorubicin 6 mg, cisplatin 30
146 mg and oxaliplatin 120 mg per m² of body surface area (BSA)) were studied according to data
147 of phase I safety studies and clinical use [10 - 12]. A patient with a height of 1.90 m and a

148 weight of 100 kg was assumed as scenario. The BSA was calculated according to the DuBois
149 formula [13]. Glucose 5% and NaCl 0.9% were purchased from B. Braun, Melsungen,
150 Germany. Oxaliplatin was diluted with glucose 5%, doxorubicin and cisplatin with NaCl
151 0.9% to a total of 50 ml and 150 ml, respectively. For blank control solution, doxorubicin
152 1.368 mg was diluted with 5 ml of 0.9% NaCl 0.9% and cisplatin 6.84 mg diluted with 15 ml
153 of 0.9% NaCl 0.9% to a total volume 20 ml. Oxaliplatin 36.48 mg was diluted with 20 ml of
154 5% Glucose. Blank control solutions were immediately filled into sterile glass bottles (ref. #
155 FRAA-250-60, Labbox GmbH, Düsseldorf, Germany) and stored protected from light at 4 °C.
156 The chemotherapy solutions for nebulization experiments were filled into syringes (ELS 200
157 ml (S), MEDTRON AG, Saarbrücken, Germany), the syringe instated into the high-pressure
158 injector head (Accutron[®] HP-D Vision, MEDTRON AG, Saarbrücken, Germany), vented and
159 then connected to the high-pressure line of the MDN (Quattro Jet[™], REGER Medizintechnik
160 GmbH, Villigendorf, Germany). The shaft of the MDN was wrapped with sterile surgical
161 compress proximal to the head of the nebulizer and then positioned vertically in a tight and
162 stable position in the neck of a sterile 250 ml glass bottle (ref. # FRAA-250-60, Labbox
163 GmbH, Düsseldorf, Germany). Nebulization could take place unhindered with the nebulizer
164 head in the body of the bottle at a flow rate of 1.5 ml/s with an upper pressure limit of 300 psi.
165 Nebulization was undertaken under a vertical laminar air flow bench. Doxorubicin and
166 Cisplatin were nebulized one after the other but into the sample bottle. All experiments were
167 performed in triplicates. The sample and blank control solution bottles were sealed air tight
168 immediately after the experiments and stored protected from light at 4°C. Transport of the
169 samples to the laboratory for further processing by courier within 4 hours while refrigeration
170 was maintained.

171 *2.3 Chemical characterisation and toxicological risk assessment:* The MDN device was
172 categorised according to ISO 10993-1:2018 and the chemical characterisation was performed

173 according to ISO 10993-18:2020. Head-Space Gas Chromatography coupled with Mass
174 Spectrometry (HSGC-MS) were used for detection of volatile organic compounds, Gas
175 Chromatography coupled with Mass Spectrometry (GC-MS) for detection of semi volatile
176 organic compounds, Liquid Phase Chromatography coupled to a Mass Spectrometer (LC-
177 MS) for detection of non-volatile organic compounds, Inductively Coupled Plasma Atomic
178 Emission Spectrometry (ICP-OES) for quantification of the inorganic elements and Ion
179 Chromatography (IC) for quantification of the ions. The Analytical Evaluation Threshold
180 (AET) according to ISO 10993-18:2020 was applied. AET defines the threshold below which
181 leachable or extractable substances cannot be identified or quantified and therefore it can be
182 assumed without further evaluation that such a substance does not pose a toxicological risk.

183 The parameters used for the toxicological risk assessment were set to consider the worst case.
184 Three consecutive MDN-PIPAC administrations were assumed with no time interval in
185 between (instead of a treatment interval of four to six weeks between each PIPAC cycle). In
186 addition, the exposure of children with a body weight of 10 kg was calculated with the
187 amount used for the treatment of an adult. The toxicological risk associated with leachables
188 was assessed by collecting data and identifying critical health endpoints through literature
189 searches and toxicological risk assessment from PubChem (HSDB), PubMed, ChemIDplus,
190 ECHA databases and various other online sources and databases (e.g., FDA.gov) in
191 accordance with ISO 10993-17:2002

192 *2.4 Preclinical assessment of the MDN-PIPAC safety checklist and Schlieren imaging:* As
193 a first step, a team of two surgeons and one PIPAC nurse analysed whether the use of the
194 MDN could result in additional intraoperative risks or hazards for healthcare personnel.
195 Potential risks were assessed for clinical relevance. Appropriate safety measures were then
196 developed and integrated into our existing intraoperative PIPAC safety checklist [14]. In order
197 to check whether a mispositioning of the MDN head in the trocar shaft could lead to a

198 possible retrograde leakage of chemotherapy aerosol into the environment, we additionally
199 performed ex-vivo streaking studies on an established PIPAC model [15]. In a second step,
200 using this adapted intraoperative PIPAC safety checklist, the team repeatedly simulated
201 MDN-PIPAC applications in the operating room using NaCl 0.9% (B. Braun, Melsungen,
202 Germany) on an established ex-vivo PIPAC model [15] to test the coherence of the adapted
203 intraoperative PIPAC safety measures and the safety checklist. In summary, a final
204 intraoperative MDN-PIPAC safety checklist was developed for in- vivo animal experiments.

205 *2.5 In-vivo animal MDN-PIPAC and CT-peritoneography:*

206 Domestic pigs were handled and cared for according to all relevant guidelines by authorised
207 investigators. The study (file # 40583) was approved by the French Ministry of Higher
208 Education and Research (Ministère de l'enseignement supérieur et de la recherche). A total of
209 three male animals weighing from 47 to 42 kg were used. Anaesthesia was induced by
210 intramuscular injection of ketamine 20 mg/kg, xylazine 2 mg/kg, and a subcutaneous injection
211 of atropine 0.02 mg/kg, and then completed by endotracheal intubation. Animals were
212 maintained under anaesthesia by isoflurane 3%, intravenous sufentanil, and cisatracurium.
213 The animals were fixed in a supine position in the CT-scanner (SOMATOM Definition AS
214 128, Siemens, Germany) to deliver HP/HD PIPAC described previously [12]. The MDN was
215 placed at the centre of the abdomen in a perpendicular position so that the horizontal nozzle
216 openings protruded approx. 7 mm beyond the end of the 12-mm trocar. The orientation of
217 these horizontal nozzle openings was chosen so that one nozzle was directed into the right and
218 left upper abdomen and the third nozzle into the small pelvis. Another 5-mm trocar was
219 inserted into the abdominal cavity to monitor the position of the nozzle head with a 5 mm
220 camera and the nebulization process. CT-peritoneography was performed using a modified
221 technique previously described [16]. For this purpose, 100 ml Imeron[®] 300 (Bracco Imaging
222 GmbH, Konstanz, Germany) was diluted in 900 ml NaCl 0.9% (B Braun, Melsungen,

223 Germany) in a ratio of 1:10. 150 ml of this solution was then administered for HP/HP-PIPAC
224 CT-peritoneography at a flow rate of 1.5 ml/s (Accutron CT-D Vision, MEDTRON AG,
225 Saarbrücken, Germany). CT-peritoneography was performed immediately at the end of
226 HP/HD-PIPAC. After CT acquisition, the animals were immediately euthanized by
227 intravenous injection of phenobarbital.

228 *2.6 Patients' selection criteria for MDN-PIPAC:* The clinical study was performed in line
229 with the guidelines of the Declaration of Helsinki at the Department of Surgery, Klinikum
230 Dortmund, University Hospital of the University Witten/Herdecke, Germany. All patients
231 gave oral and written informed consent. For the clinical trial, the approval of the Ethics
232 Committee of the Medical Faculty of the University of Münster/Medical Association
233 Westphalia-Lippe in Germany (file # 2021-360-f-s) and the German Clinical Trials Register
234 at <https://www.drks.de/DRKS00033077> was obtained.

235 All patients had histologically confirmed primary or metastatic peritoneal surface
236 malignancies (PSM). Patients were selected by a multidisciplinary tumor board accredited by
237 the German Society for General and Visceral Surgery (DGAV). The inclusion criteria have
238 already been described in detail [10]. The time interval between cycles was between four to
239 six weeks. Systemic chemotherapy was discontinued one week prior and after MDN-PIPAC.
240 Patients were informed that PIPAC treatment was not provided within the framework of
241 evidence-based therapy guidelines. All patients gave their oral and written consent. All
242 procedures were performed as previously described in detail [10, 12] and were performed by
243 one senior surgeon (J.Z.). Oxaliplatin at a dose of 120.0 mg/m² body surface area (BSA)
244 diluted in a total of 150 ml glucose 5% was administered in case of PSM of colorectal and
245 appendiceal primary tumours. For all other tumour entities, doxorubicin 6.0 mg/m² BSA
246 diluted in 50 ml NaCl 0.9% followed by cisplatin 30.0 mg/m² BSA diluted in 150 ml NaCl
247 0.9% [10 - 12]. According to the manufacturer's instructions for use, the MDN was operated

248 at a liquid fluid volume flow of 1.5 ml/s with an upper pressure limit of 300 psi. Access to the
249 peritoneal cavity was always obtained via an infraumbilical open Hasson approach. Before
250 starting the drug nebulization, the capnoperitoneal pressure was increased from 12 to 20
251 mmHg and then kept constant for 30 minutes.

252 *2.7 Perioperative short-term outcome and data acquisition:* Retrospective data acquisition
253 of a consecutive case series of 30 patients. The entire staging laparoscopy, including
254 documentation of the Sugarbaker PCI score, the amount of ascites and the quality of
255 chemotherapy nebulization, is monitored by video according to our standards for
256 intraoperative documentation. All data are stored electronically in the patient's record. Data
257 acquisition and data base management is carried out by J. Z. as part of the required quality
258 assurance as a certified centre of the DGAV. Perioperative adverse events are graded
259 according to the Clavien-Dindo Classification [13, 14]. Data are expressed as absolute
260 numbers whereas continuous data are expressed as medians (range).

261

262 **3.0 RESULTS**

263 *3.1 Chemical characterisation and toxicological risk assessment:* The results of the
264 chemical analyses of nebulized chemotherapy solutions are summarized in Table 1.

265 The independent systematic toxicological risk assessment based on the assumption of three
266 consecutive PIPAC sessions on the same day in a child with a body weight of 10 kg revealed
267 no toxicological risk for the few compounds detected after nebulization.

268 *3.2 Preclinical technical, safety checklist and surgical approach assessment for MDN-*
269 *PIPAC:* The following three relevant sub-areas were defined and perioperative measures
270 implemented as follows:

271 3.2.1 *Operational parameters:* According to previous research data and the manufacturer's
272 specifications, the MDN is operated best with pressure of 150-250 psi with an upper
273 safety limit pressure of 300 psi. In practice this pressure operating window
274 corresponds to the liquid volume flowrate of 1.2 ml/s - 1.6 ml/s. [2]. Accordingly,
275 these operating parameters were stored in the high-pressure injector as a separate
276 MDN-PIPAC working programme. As there are no other differences in handling and
277 technical operation compared to the conventional nebulizer used, no additional
278 measures were necessary.

279 3.2.2 *Construction & Design:* Due to the three horizontal nozzles, there is a potential risk of
280 drug nebulization in the trocar if the horizontal nozzles are not placed sufficiently
281 beyond the distal end of the trocar into the abdominal cavity. In the worst case,
282 retrograde leakage of chemotherapy through the trocar valve into the operating theatre
283 could occur and harm healthcare workers. To avoid this, the correct positioning of the
284 nebulizer head in the trocar has been added to our standard safety checklist. The four-
285 eye principle is used to check that the horizontal nozzles extend beyond the most distal
286 point of the trocar. It should be noted that most trocars are bevelled at an angle of
287 approximately 15°. The most distal end of the trocar is therefore used as the reference
288 point (Figure 1A).

289 3.2.3 *Surgical approach:* To optimize spatial aerosol distribution during MDN-PIPAC, the
290 spraying distance between the nozzle orifice and the peritoneum should be as large as
291 possible [2, 7]. Periumbilical, perpendicular placement of the MDN is therefore ideal,
292 if surgically possible (Figure 2A). Additionally, we decided to orientate the MDN in
293 that way that one horizontal spray jet pointed to the right upper and a second to the left
294 upper abdominal quadrant and the third towards the small pelvis (Figure 2B). In
295 addition, we decided to routinely fix the nebulizer intraoperatively in a single-arm

296 holder (M-TRAC, Braun, Melsungen, Germany) to further prevent tilting and axial
297 sliding in the trocar. The central periumbilical perpendicular MDN position as well as
298 the orientation of the horizontal nozzle orifices were integrated into our intraoperative
299 safety checklist.

300 *2.3 Ex-vivo MDN-PIPAC simulation and Schlieren imaging:* As the distal end of the
301 trocar is angled, special care must be taken to ensure that the distal end of the trocar is visible
302 intraoperatively so as not to interfere with the nebulization of the horizontal nozzles. The
303 correct position of the MDN head has therefore been included as a separate item in our
304 extended safety checklist. The openings of the horizontal nozzles must extend at least 7 mm
305 beyond the distal end of the trocar to avoid interference during nebulization (Figure 1 A). In
306 addition, the vertical position of the MDN in the 10/12-mm trocar was found to cause the
307 MDN to tend to slide inward in the trocar without additional fixation. To avoid MDN slippage
308 into the trocar, the device is placed on the trocar head with a rubber ring (sterile, reusable
309 trocar seal) previously pulled over the shaft of the nebulizer in such a way that the rubber ring
310 fits tightly on the trocar head and prevents the nebuliser from slipping inside the trocar
311 (Figure 1 B). To further stabilize the position of the MDN, the use of a single-arm holder
312 turned out to be essential and was therefore also included in our safety checklist. In addition,
313 it was investigated whether a mispositioning of the MDN head with the horizontal nozzles
314 nebulizing in the trocar shaft could cause aerosol leakage into the environment but multiple
315 simulations of such a scenario showed visually no detectable retrograde aerosol leakage into
316 the environment.

317 *2.4 In-vivo pig MDN-PIPAC CT-peritoneography:* The CT-peritoneographies of the three
318 pigs could be performed without perioperative complications. The animals showed no
319 cardiorespiratory problems due to the capnoperitoneal pressure of 20 mmHg. Our previously
320 prepared MDN-PIPAC safety checklist was implemented without any problems. The

321 subsequent CT-peritoneographies showed an excellent distribution pattern of the administered
322 contrast agent aerosol. However, no contrast agent was visible in the ventral portions of the
323 abdominal cavity. Figure 3 depicts representative images of pig N° 1.

324 *2.5 Clinical baseline characteristics:* A total of 21 patients (male/female ratio: 2:1) with a
325 mean age of 62 (range: 38-86) years underwent 30 consecutive MDN-PIPACs. ECOG 0 and 1
326 were seen in five and 16 patients, respectively. Patients had PSM of the upper gastrointestinal
327 tract (n = 6), ovarian cancer (n = 4), colorectal cancer (n = 3), hepato-pancreatico-biliary tract
328 (n = 3), malignant epithelioid peritoneal mesothelioma (n = 2) and other (n = 3). Eleven
329 patients had metachronous PSM. Prior to MDN-PIPAC, seventeen patients had undergone
330 primary tumor resection. The median number of patients had 2 (range: 1-5) lines of systemic
331 chemotherapy before undergoing MDN-PIPAC. Seven patients had previously undergone a
332 median of 2 (range: 1 - 4) PIPACs with the conventional PIPAC nebulizer in our institutions.
333 The patients' preoperative baseline data are listed in Table 2.

334 *2.6 MDN-PIPAC procedure details, morbidity, and mortality:* Abdominal access was
335 achieved in all patients. Thirteen, seven and one patient underwent one, two and three MDN-
336 PIPACs, respectively. Two patients received only one cycle of MDN-PIPAC because they
337 were considered candidates for cytoreductive surgery (CRS) and heated intraperitoneal
338 chemotherapy (HIPEC) at the time of staging laparoscopy for MDN-PIPAC.

339 The median Sugarbaker PCI score and ascites at the first MDN-PIPAC were 25 (1-35) and
340 200 ml (0 - 800ml), respectively. The overall mean (range) operative time was 52.3 (48 - 78)
341 minutes. The gradual pressure build-up and the subsequent exposure phase of 30 minutes at a
342 capnoperitoneal pressure of 20 mmHg were well tolerated. No patient showed signs of cardio-
343 respiratory impairment from the procedure. No intraoperative surgical or technical problems
344 occurred.

345 In total, four patients suffered grade I (Dindo-Clavien) complications after a total of 30 MDN-
346 PIPACs (4/30). Three patients experienced persistent nausea and vomiting postoperatively,
347 requiring prolonged intravenous rehydration and antiemetic therapy (without gastric tube) for
348 48 hours postoperatively. Another patient complained of abdominal pain, which could also be
349 managed after extending intravenous analgesic therapy. No complications > grade 1 were
350 observed. The German health system requires a minimum hospitalization of 3 days for PIPAC
351 application in order to be fully reimbursed by the health insurance companies. All patients
352 were discharged on the third postoperative day at home.

353

354 **4.0 DISCUSSION**

355 For more than a decade, a PIPAC nebulizer has been available for off-label clinical use. This
356 technology, with an axially mounted nebulizer unit, has become the standard PIPAC device.
357 Due to its design and performance characteristics, the distribution pattern of the atomized
358 chemotherapy is not homogeneous. Below the opening of the nebulizer unit, approximately
359 97% by volume is deposited directly onto the underlying peritoneum by inertial impaction [4,
360 19 - 22]. Recently, other PIPAC nebulizers have become available on the market. However,
361 all nebulizers are based on the same/similar design as the standard technology. Therefore, the
362 problem of local chemotherapy accumulation and inhomogeneous drug distribution pattern in
363 the peritoneal cavity remains unresolved [2], which may affect the oncological efficacy of
364 PIPAC [23]. Therefore, the optimal position of the standard PIPAC nozzle has been
365 investigated in recent years in order to optimize the spatial distribution of chemotherapy [14,
366 24, 25]. More recently, new experimental PIPAC nozzle technologies have been developed.
367 Rotational intraperitoneal pressure aerosol chemotherapy (RIPAC) uses a modified nebulizer
368 technology similar to the standard PIPAC nebulizer. However, to optimize drug distribution,
369 the nozzle rotates 30° around its vertical axis in the abdominal cavity. In-vivo large animal

370 data indicate, that RIPAC leads to a significantly more homogeneous distribution pattern and
371 higher penetration depths of doxorubicin into the tissue compared to the standard PIPAC [26,
372 27]. Another experimental approach is the use of a preclinical multi-directional nebulizer
373 (MDN). Braet et al. observed in an ex-vivo PIPAC model that the use of their experimental
374 MDN device improved the spatial drug distribution of nebulized nanoparticles compared to
375 standard PIPAC technology [28].

376 Based on these experimental data, it seems obvious that PIPAC nozzles, which optimize drug
377 distribution, could also be promising in clinical application. For some time now, a FDA and
378 CE Class IIa certified MDN has been available for off-label clinical use of MDN-PIPAC [2].
379 We carried out extensive preclinical testing before introducing this new device into our daily
380 practice.

381 After the premature discontinuation (<https://clinicaltrials.gov/study/NCT04065139>) of a
382 French prospective, randomized phase II study (PIPAC EstoK 01) [29], it was vividly
383 discussed whether toxic substances could arise during the application of PIPAC due to the
384 interaction of the chemotherapy solution with the PIPAC nebulizer/syringe/tube system.
385 Therefore, independent toxicological investigations were performed as a first step. For the
386 worst-case scenario with the highest chemotherapy doses, the toxicological investigations
387 showed that no relevant toxicologically questionable substances were observed. The risk
388 assessment was further based on the assumption that three PIPACs are administered
389 consecutively on one day to a patient with a body weight of 10 kg. Even this extreme scenario
390 did not reveal any cumulative toxicological risk for patients. Furthermore, these data indicate
391 that the MDN device could also be used in children with a body weight > 10 kg. It is
392 important to emphasize that our toxicological data are only valid for this type of nozzle.
393 According to our current knowledge, there are no data available for other types of nebulizers.

394 Our further technical analysis with PIPAC surgeons and scrub nurses in our department
395 showed that the handling of the MDN differs only slightly from that of the standard nebulizer.
396 The MDN unit requires a higher flow rate which can be programmed into the high-pressure
397 injector. However, a major difference is the three additional nozzles built horizontally into the
398 MDN head. Repetitive ex vivo simulations have shown that the correct mounting of the
399 nozzle head is crucial. The lateral openings of the nebulizers must protrude at least 7 mm
400 beyond the distal end of the trocar for correct atomization. Moreover, we observed that the
401 MDN can slip into the trocar due to the increased weight of the device. Therefore, we have
402 added a sterile rubber ring to the MDN that is pulled over the nozzle and positioned so that it
403 rests directly on the trocar head, while at the same time achieving the ideal position for the
404 MDN head. Finally, another important safety point is the consistent use of a single-arm
405 holder, which additionally fixes the MDN in a strictly vertical position in the trocar. This
406 measure also prevents the MDN from unintentionally tilting sideways during the spraying
407 process, which could worsen the spatial distribution pattern of the drug. In order to better
408 monitor this correct position intraoperatively, it would be desirable if the manufacturer could
409 provide a safety mark indicating intraoperatively the ideal position of the MDN head. The
410 manufacturer was informed of these points to improve the administrability and safety of
411 MDN-PIPAC.

412 To further refine the intraoperative MDN-PIPAC safety checklist, based on our previous ex-
413 vivo simulations, we performed MDN-PIPAC in the large animal model immediately
414 followed by CT-peritoneography to visualize the quality of the spatial aerosol distribution.
415 The administration of all three MDN-PIPACs went without any technical or safety problems.
416 The CT-peritoneographies revealed wide aerosol deposition. In particular, areas such as the
417 omental bursa, hepatic interlobar and deep entero-enteric regions were also affected. Only the
418 ventral parts of the abdominal cavity showed no contrast. However, large gravity-dependent

419 fluid collections, as previously observed with the conventional PIPAC technique, did not
420 occur [22].

421 The clinical application of the elaborated intraoperative MDR-PIPAC safety checklist enabled
422 us to apply the procedure to thirty consecutive patients without intraoperative problems. The
423 postoperative course was characterized by four patients with minor complications (Dindo-
424 Clavien grade I). Based on this initial experience, no clinical difference from conventional
425 PIPAC was observed at our institution [12].

426 **5.0 CONCLUSION**

427 Toxicological data show that the use of the MDN does not generate any leachable substances
428 that could pose a risk to patients. Ex-vivo simulations confirm the importance of correct
429 positioning and fixation of the MDN in the trocar and, if possible, in a periumbilical position.
430 Ex-vivo streak tests show that chemotherapy aerosol does not escape from the trocar valve
431 into the operating room even if the MDN head is incorrectly positioned in the trocar shaft.
432 MDN handling is safe and poses no problems if the safety checklist is properly adapted to this
433 device. Whether such new devices will have a positive impact on clinical outcomes remains
434 uncertain. However, the superior spatial distribution of nebulized substances may have a
435 positive effect on clinical outcome. It is unlikely that there will be prospective studies in the
436 near future to clarify this issue. Therefore, we suggest that the type of nebulizer used for
437 PIPAC should also be documented in the ISSPP PIPAC database [30]. Such a large database
438 could provide insight into the role of different nebulizers used on oncological outcome.

439 **REFERENCES**

- 440 1. Di Giorgio A, Macrì A, Ferracci F, Robella M, Visaloco M, De Manzoni G, Sammartino
441 P, Sommariva A, Biacchi D, Roviello F, Pastorino R, Pires Marafon D, Rotolo S, Casella
442 F, Vaira M. 10 Years of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC): A
443 Systematic Review and Meta-Analysis. *Cancers*. 2023; 15(4):1125.
444 <https://doi.org/10.3390/cancers15041125>
- 445 2. Daniel Göhler, Kathrin Oelschlägel, Mehdi Ouaiissi, Urs Giger-Pabst. Performance of
446 different nebulizers in clinical use for Pressurized Intraperitoneal Aerosol Chemotherapy
447 (PIPAC). medRxiv 2023.03.24.23287646; doi:
448 <https://doi.org/10.1101/2023.03.24.23287646>
- 449 3. Nadiradze G, Horvath P, Sautkin Y, Archid R, Weinreich F-J, Königsrainer A, Reymond
450 MA. Overcoming Drug Resistance by Taking Advantage of Physical Principles:
451 Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC). *Cancers*. 2020; 12(1):34.
452 <https://doi.org/10.3390/cancers12010034>
- 453 4. Göhler D, Khosrawipour V, Khosrawipour T, Diaz-Carballo D, Falkenstein TA, Zieren J,
454 Stintz M, Giger-Pabst U. Technical description of the microinjection pump (MIP®) and
455 granulometric characterization of the aerosol applied for pressurized intraperitoneal
456 aerosol chemotherapy (PIPAC). *Surg Endosc*. 2017 Apr;31(4):1778-1784. doi:
457 10.1007/s00464-016-5174-5. Epub 2016 Sep 8. PMID: 27631320.
- 458 5. Tempfer CB, Rezniczek GA, Ende P, Solass W, Reymond MA. Pressurized
459 Intraperitoneal Aerosol Chemotherapy with Cisplatin and Doxorubicin in Women with
460 Peritoneal Carcinomatosis: A Cohort Study. *Anticancer Res*. 2015 Dec;35(12):6723-9.
461 doi: 10.1055/s-0035-1560004. PMID: 26637888.
- 462 6. Tavernier C, Passot G, Vassal O, Allaouchiche B, Decullier E, Bakrin N, Alyami M,
463 Davigo A, Bonnet JM, Louzier V, Paquet C, Glehen O, Kepenekian V. Pressurized
464 intraperitoneal aerosol chemotherapy (PIPAC) might increase the risk of anastomotic

- 465 leakage compared to HIPEC: an experimental study. *Surg Endosc.* 2020 Jul;34(7):2939-
466 2946. doi: 10.1007/s00464-019-07076-3. Epub 2019 Aug 27. PMID: 31456025.
- 467 7. Davigo A, Passot G, Vassal O, Bost M, Tavernier C, Decullier E, Bakrin N, Alyami M,
468 Bonnet JM, Louzier V, Paquet C, Allaouchiche B, Glehen O, Kepenekian V. PIPAC
469 versus HIPEC: cisplatin spatial distribution and diffusion in a swine model. *Int J*
470 *Hyperthermia.* 2020;37(1):144-150. doi: 10.1080/02656736.2019.1704891. PMID:
471 32003300.
- 472 8. Graversen M, Rouvelas I, Ainsworth AP, Bjarnesen AP, Detlefsen S, Ellebaek SB,
473 Fristrup CW, Liljefors MG, Lundell L, Nilsson M, Pfeiffer P, Tarpgaard LS, Tsekrekos A,
474 Mortensen MB. Feasibility and Safety of Laparoscopic D2 Gastrectomy in Combination
475 with Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) in Patients with Gastric
476 Cancer at High Risk of Recurrence-The PIPAC-OPC4 Study. *Ann Surg Oncol.* 2023 Mar
477 3. doi: 10.1245/s10434-023-13278-w. Epub ahead of print. PMID: 36867174.
- 478 9. Braet, Helena and Andretto, Valentina and Mariën, Remco and Yücesan, Beyza and
479 Haegebaert, Ragna and Lollo, Giovanna and De Smedt, Stefaan C. and Remaut, Katrien,
480 The Effect of Electrostatic High Pressure Nebulization (ePIPAC) on the Stability, Activity
481 and Ex Vivo Distribution of Ionic Self-Assembled Nanomedicines. Available at SSRN:
482 <https://ssrn.com/abstract=4418821> or <http://dx.doi.org/10.2139/ssrn.4418821>
- 483 10. Guowei Kim, Hon Lyn Tan, Raghav Sundar, Bettina Lieske, Cheng Ean Chee, Jingshan
484 Ho, Asim Shabbir, Maria V. Babak, Wee Han Ang, Boon Cher Goh, Wei Peng Yong,
485 Lingzhi Wang and Jimmy B.Y. So. PIPAC-OX: A Phase I Study of Oxaliplatin-Based
486 Pressurized Intraperitoneal Aerosol Chemotherapy in Patients with Peritoneal Metastases.
487 *Clin Cancer Res* April 1 2021 (27) (7) 1875-1881; DOI: 10.1158/1078-0432.CCR-20-
488 2152

- 489 11. Robella M, De Simone M, Berchiolla P, Argenziano M, Borsano A, Ansari S, Abollino O,
490 Ficiarà E, Cinquegrana A, Cavalli R, Vaira M. A Phase I Dose Escalation Study of
491 Oxaliplatin, Cisplatin and Doxorubicin Applied as PIPAC in Patients with Peritoneal
492 Carcinomatosis. *Cancers (Basel)*. 2021 Mar 3;13(5):1060. doi: 10.3390/cancers13051060.
493 PMID: 33802269; PMCID: PMC7958944.
- 494 12. Ramos Arias G, Sindayigaya R, Ouaiissi M, Buggisch JR, Schmeding M, Giger-Pabst U,
495 Zieren J. Safety and Feasibility of High-Pressure/High-Dose Pressurized Intraperitoneal
496 Aerosol Chemotherapy (HP/HD-PIPAC) for Primary and Metastatic Peritoneal Surface
497 Malignancies. *Ann Surg Oncol*. 2022 Nov 18. doi: 10.1245/s10434-022-12698-4. Epub
498 ahead of print. PMID: 36400887.
- 499 13. Du Bois, D. and Du Bois, E.F. (1916) A Formula to Estimate the Approximate Surface
500 Area if Height and Weight Be Known. *Archives of Internal Medicine*, 17, 863-871.
501 <http://dx.doi.org/10.1001/archinte.1916.00080130010002>
- 502 14. Giger-Pabst U, Tempfer CB. How to Perform Safe and Technically Optimized Pressurized
503 Intraperitoneal Aerosol Chemotherapy (PIPAC): Experience After a Consecutive Series of
504 1200 Procedures. *Journal of Gastrointestinal Surgery: Official Journal of the Society for*
505 *Surgery of the Alimentary Tract*. 2018 Dec;22(12):2187-2193.
- 506 15. Solaß, W., Giger-Pabst, U., Zieren, J. et al. Pressurized Intraperitoneal Aerosol
507 Chemotherapy (PIPAC): Occupational Health and Safety Aspects. *Ann Surg Oncol* 20,
508 3504–3511 (2013). <https://doi.org/10.1245/s10434-013-3039-x>
- 509 16. Meyers, M.A. (1976). Peritoneography: Normal and Pathologic Anatomy. In: *Dynamic*
510 *Radiology of the Abdomen*. Springer, New York, NY. [https://doi.org/10.1007/978-1-](https://doi.org/10.1007/978-1-4757-3955-8_3)
511 [4757-3955-8_3](https://doi.org/10.1007/978-1-4757-3955-8_3)
- 512 17. Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new
513 proposal with evaluation in a cohort of 6336 patients and results of a survey. *Ann Surg*.

- 514 2004 Aug;240(2):205-13. doi: 10.1097/01.sla.0000133083.54934.ae. PMID: 15273542;
515 PMCID: PMC1360123.
- 516 18. Clavien PA, Barkun J, de Oliveira ML, Vauthey JN, Dindo D, Schulick RD, de
517 Santibañes E, Pekolj J, Slankamenac K, Bassi C, Graf R, Vonlanthen R, Padbury R,
518 Cameron JL, Makuuchi M. The Clavien-Dindo classification of surgical complications:
519 five-year experience. *Ann Surg.* 2009 Aug;250(2):187-96. doi:
520 10.1097/SLA.0b013e3181b13ca2. PMID: 19638912.
- 521 19. Khosrawipour V, Khosrawipour T, Diaz-Carballo D, Förster E, Zieren J, Giger-Pabst U.
522 Exploring the Spatial Drug Distribution Pattern of Pressurized Intraperitoneal Aerosol
523 Chemotherapy (PIPAC). *Ann Surg Oncol.* 2016 Apr;23(4):1220-4. doi: 10.1245/s10434-
524 015-4954-9. Epub 2015 Nov 9. PMID: 26553440.
- 525 20. Axel Davigo, Guillaume Passot, Olivia Vassal, Muriel Bost, Clément Tavernier, Evelyne
526 Decullier, Naoual Bakrin, Mohammad Alyami, Jeanne-Marie Bonnet, Vanessa Louzier,
527 Christian Paquet, Bernard Allaouchiche, Olivier Glehen & Vahan Kepenekian (2020)
528 PIPAC versus HIPEC: cisplatin spatial distribution and diffusion in a swine model,
529 *International Journal of Hyperthermia*, 37:1, 144-150, DOI:
530 10.1080/02656736.2019.1704891
- 531 21. Giger-Pabst U, Bucur P, Roger S, Falkenstein TA, Tabchouri N, Le Pape A, Lerondel S,
532 Demtröder C, Salamé E, Ouaiissi M. Comparison of Tissue and Blood Concentrations of
533 Oxaliplatin Administrated by Different Modalities of Intraperitoneal Chemotherapy. *Ann*
534 *Surg Oncol.* 2019 Dec;26(13):4445-4451. doi: 10.1245/s10434-019-07695-z. Epub 2019
535 Aug 9. PMID: 31399820.
- 536 22. Bellendorf A, Khosrawipour V, Khosrawipour T, Siebigtheroth S, Cohnen J, Diaz-Carballo
537 D, Bockisch A, Zieren J, Giger-Pabst U. Scintigraphic peritoneography reveals a non-
538 uniform ^{99m}Tc-Perchnetat aerosol distribution pattern for Pressurized Intra-Peritoneal

- 539 Aerosol Chemotherapy (PIPAC) in a swine model. *Surg Endosc.* 2018 Jan;32(1):166-174.
540 doi: 10.1007/s00464-017-5652-4. Epub 2017 Jun 22. PMID: 28643076.
- 541 23. Dedrick RL, Flessner MF. Pharmacokinetic problems in peritoneal drug administration:
542 tissue penetration and surface exposure. *J Natl Cancer Inst.* 1997 Apr 2;89(7):480-7. doi:
543 10.1093/jnci/89.7.480. PMID: 9086004.
- 544 24. Khosrawipour V, Khosrawipour T, Falkenstein TA, Diaz-Carballo D, Förster E, Osma A,
545 Adamietz IA, Zieren J, Fakhrian K. Evaluating the Effect of Micropump[®] Position,
546 Internal Pressure and Doxorubicin Dosage on Efficacy of Pressurized Intra-peritoneal
547 Aerosol Chemotherapy (PIPAC) in an Ex Vivo Model. *Anticancer Res.* 2016
548 Sep;36(9):4595-600. doi: 10.21873/anticancerres.11008. PMID: 27630300.
- 549 25. Piao J, Park SJ, Lee H, Kim J, Park S, Lee N, Kim SI, Lee M, Song G, Lee JC, Kim HS;
550 KORIA TRIAL GROUP. Ideal Nozzle Position During Pressurized Intraperitoneal
551 Aerosol Chemotherapy in an Ex Vivo Model. *Anticancer Res.* 2021 Nov;41(11):5489-
552 5498. doi: 10.21873/anticancerres.15362. PMID: 34732419.
- 553 26. Mun J, Park SJ, Kim HS. Rotational intraperitoneal pressurized aerosol chemotherapy in a
554 porcine model. *Gland Surg.* 2021 Mar;10(3):1271-1275. doi: 10.21037/gs-2019-ursoc-11.
555 PMID: 33842275; PMCID: PMC8033043.
- 556 27. Park SJ, Lee EJ, Lee HS, Kim J, Park S, Ham J, Mun J, Paik H, Lim H, Seol A, Yim GW,
557 Shim SH, Kang BC, Chang SJ, Lim W, Song G, Kim JW, Lee N, Park JW, Lee JC, Kim
558 HS; KoRIA* trial group. Development of rotational intraperitoneal pressurized aerosol
559 chemotherapy to enhance drug delivery into the peritoneum. *Drug Deliv.* 2021
560 Dec;28(1):1179-1187. doi: 10.1080/10717544.2021.1937382. PMID: 34121568; PMCID:
561 PMC8204987.
- 562 28. Braet H, Andretto V, Mariën R, Yücesan B, van der Vegte S, Haegebaert R, Lollo G, De
563 Smedt SC, Remaut K. The effect of electrostatic high-pressure nebulization on the

Kockelmann et al. - Version V3

564 stability, activity and ex vivo distribution of ionic self-assembled nanomedicines. *Acta*
565 *Biomater.* 2023 Aug 19:S1742-7061(23)00492-0. doi: 10.1016/j.actbio.2023.08.027. Epub
566 ahead of print. PMID: 37598790.

567 29. Eveno C, Jouvin I, Pocard M. PIPAC EstoK 01: Pressurized IntraPeritoneal Aerosol
568 Chemotherapy with cisplatin and doxorubicin (PIPAC C/D) in gastric peritoneal
569 metastasis: a randomized and multicenter phase II study. *Pleura Peritoneum.* 2018 Jun
570 21;3(2):20180116. doi: 10.1515/pp-2018-0116. PMID: 30911659; PMCID:
571 PMC6405009.

572 30. Mortensen MB, Glehen O, Horvath P, Hübner M, Hyung-Ho K, Königsrainer A, Pocard
573 M, Reymond MA, So J, Fristrup CW. The ISSPP PIPAC database: design, process,
574 access, and first interim analysis. *Pleura Peritoneum.* 2021 Apr 22;6(3):91-97. doi:
575 10.1515/pp-2021-0108. PMID: 34676282; PMCID: PMC8482445.

576

577 **Figures and Tables**

578 **Table 1:** Toxicological analyses after nebulization of chemotherapy with the MDN

	Doxorubicin + Cisplatin	Oxaliplatin
HSGC-MS analysis for Volatile Organic Compounds	Not detected	Not detected
GC-MS analysis for Semi-Volatile Organic Compounds		
- 1,6,11,16-Tetraoxacycloeicosane	Not detected	0.03 µg/ml
- 1,6,11,16,21-Pentaoxacyclopentacosane	Not detected	0.04 µg/ml
LC-MS analysis for Non-Volatile Organic Compounds		
- Cyclic polybutylene glycol (C20)	0.144 µg/ml	0.131 µg/ml
- Cyclic polybutylene glycol (C24)	0.246 µg/ml	0.123 µg/ml
- Cyclic polybutylene glycol (C32)	0.083 µg/ml	0.045 µg/ml
ICP-MS analysis for inorganic elements		
- Cu	0.049 µg/ml	Not detected
- Fe	0.057 µg/ml	0.011 µg/ml
- Mn	0.015 µg/ml	0.014 µg/ml
IC analysis for anions		
- Acetates	Not detected	Not detected
- Fluorides	Not detected	Not detected
- Chlorides	Not detected	Not detected
- Bromides	Not detected	Not detected
- Nitrites	Not detected	Not detected
- Nitrates	Not detected	Not detected
- Sulfates	Not detected	Not detected
- Phosphates	Not detected	Not detected

579

580 *Legend: HSGC-MS = Head-space Gas Chromatography coupled with Mass Spectrometry;*

581 *GC-MS = Gas Chromatography coupled with Mass Spectrometry; LC-MS = Liquid phase*


582 *chromatography coupled to a Mass Spectrometer; ICP-OES = Inductively Coupled Plasma*

583 *Atomic Emission Spectrometry; IC = Ion Chromatography; Cu = Copper; Fe = Ferrum; Mn*

584 *= Manganese*

585

586 **Figure 1:** *Ex vivo* evaluation of the optimal position of the MDN in the 12-mm trocar



587

588 *Legend: A = MDN inserted into a 12 mm balloon trocar. The position of the MNN head must*
589 *be checked visually so that the lateral nozzles do not nebulize into the trocar. White triangles*
590 *mark the distal end of the trocar. Note that the trocar is angled 15° at the distal end. Black*
591 *arrows point to the horizontal nozzle openings. These should protrude at least 7 mm beyond*
592 *the most distal end of the trocar (left white arrow). B = MDN inserted into a 12 mm balloon*
593 *trocar. The black arrow points to the sterile rubbering ring pulled over the nebulizer shaft*
594 *and that rests on the trocar head to avoid gliding of the nebulizer in the trocar.*

595

596

597

598

599


600

601

602


603

604 **Figure 2:** Periumbilical position of the MDN for optimized nebulization



606 *Legend: A = Sketch of infraumbilical position of the MDN for optimized nebulization of all*
607 *four nozzles; B = intraoperative view on the MDN head*

609 **Figure 3:** Representative MDN-PIPAC CT-peritoneography images of pig N° 1



610

611 *Legend: A1-C1 = horizontal section planes; A2-C2 = coronal section planes. White triangles*
612 *indicate to contrast agent accumulation: A1-C1 = enter-enteric and paracolic left; A2 =*
613 *subdiaphragmatic bilateral; B2 = homogeneous on the Glisson capsule, subhepatic and*
614 *interlobar; C2 = perigastric and perilienal*

615 **Table 2:** Baseline clinical characteristics of the patients with MDN-PIPAC

Variables	Total population (n = 21)
Age at first MDN-PIPAC (years, mean (range))	62 (38-86)
Primary origin (n)	
- Colo-Rectal	3
- UGI	6
- HPB	3
- MPM	2
- Ovarian	4
- Other	3
ECOG (n)	
- 0	5
- 1	16
Synchronous PSM (n)	10
Prior primary tumor resection (n)	17
Prior systemic chemotherapy lines (median, range)	2 (1-5)
Prior standard PIPAC applications before MDP-PIPAC (median, range)	1 (1-4)
Ongoing systemic chemotherapy between MDN-PIPAC procedures (n)	14
Time between primary and metachronous PSM diagnosis (months, median (range))	21 (2-56)

616

617 *Legend: PIPAC = pressurized intraperitoneal aerosol chemotherapy; MDN = multi-*
 618 *directional nebulizer; UGI = upper gastrointestinal; HPB = hepato- biliary tract; ECOG =*
 619 *Eastern Cooperative Oncology Group performance status; PSM = peritoneal surface*
 620 *malignancy*